James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's Wegovy, could improve muscle mass and overall body ...

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

In contrast, patients treated with the Allurion Balloon and Allurion Virtual Care Suite have not only lost weight but have also maintained or even gained lean body mass. The CEO of Allurion ...

In contrast, patients treated with the Allurion Balloon and Allurion Virtual Care Suite have not only lost weight but have also maintained or even gained lean body mass. The CEO of Allurion, Dr.